IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by equities researchers at Jefferies ...

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

IGM Biosciences (IGMS – Research Report) received a Hold rating and a $2.00 price target from Jefferies analyst Roger Song today. The company’s ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments. Shares were trading around $1.94. The stock is up 1.5% on the ...